5 Key Takeaways

• 1

  A case series study identified ophthalmic complications in 9 patients using semaglutide and tirzepatide, including nonarteritic anterior ischemic optic neuropathy.

• 2

  The study, led by Dr. Bradley J. Katz, found varying degrees of vision loss and optic nerve abnormalities among the patients analyzed.

• 3

  Potential mechanisms for the observed complications may include rapid glycemic control and effects on retinal GLP-1 receptors.

• 4

  The American Academy of Ophthalmology advised that patients experiencing vision loss should stop semaglutide and consult their physician.

• 5

  The study's limitations included selection bias, lack of a control group, and reliance on historical data, making causal links unclear.